The Phoenix Division

DEA Phoenix Field Division and Its Diversion-Control System

Last fully verified: July 25, 2026

The Drug Enforcement Administration’s Phoenix Field Division operates throughout Arizona through its headquarters in Phoenix and published contacts in:

Flagstaff
Lake Havasu
Nogales
Sierra Vista
Tucson
Yuma

The regional command is officially the Phoenix Field Division. There is no separate regional agency formally titled the “Phoenix Diversion Division.” Diversion Control is one of the functions carried out within the field division under the broader authority, policies, registration systems, and national leadership of DEA’s Diversion Control Division.

DEA’s public page describes the division as serving the Phoenix, Flagstaff, Lake Havasu, Nogales, Sierra Vista, Tucson, and Yuma areas. Unlike many DEA division pages, it does not simply state “Serving Arizona.” The listed offices, leadership history, and official descriptions of seven offices operating throughout Arizona nevertheless support treating Phoenix as DEA’s statewide Arizona field command.

The division’s practical identity is shaped by Arizona’s international border with Mexico, the state’s role as a trafficking corridor and distribution center, the presence of major urban and rural markets, and the continued production and movement of fentanyl, methamphetamine, cocaine, heroin, and counterfeit pharmaceutical tablets.

Its territorial operation is understandable.

Its public internal structure is incomplete.

DEA publishes an office-type legend but does not visibly classify the individual locations. It identifies current Tactical Diversion Squads in Phoenix and Tucson but does not publish a current regional Diversion Program Manager, Diversion organization chart, county assignments, or named registration and practitioner-compliance officials.

Executive Finding

What is official

DEA operates the Phoenix Field Division through a headquarters located at:

3439 East University Drive
Phoenix, Arizona 85034

Main telephone: 571-362-5600

DEA currently identifies Apolonio “Polo” Ruiz Jr. as Special Agent in Charge. Ruiz assumed command in January 2026 after previously serving as an Assistant Special Agent in Charge responsible for DEA operations in the Nogales and Tucson District Offices.

DEA publishes six subordinate Arizona contacts:

Flagstaff
Lake Havasu
Nogales
Sierra Vista
Tucson
Yuma

Together with the Phoenix headquarters, the current directory presents seven Arizona locations. DEA’s biography of former Phoenix Special Agent in Charge Cheri Oz likewise describes the division as containing seven offices throughout Arizona.

DEA’s national Tactical Diversion Squad directory identifies two Arizona squad locations:

Phoenix
Tucson

Leadership transition

Cheri Oz commanded the Phoenix Field Division beginning in March 2020.

In November 2025, DEA appointed her Assistant Administrator of the national Diversion Control Division. In that role, she became responsible for national controlled-prescription-drug and listed-chemical programs affecting approximately 2.2 million DEA registrants. Apolonio Ruiz Jr. subsequently became Phoenix Special Agent in Charge in January 2026.

The distinction is important:

Apolonio Ruiz Jr. commands the Phoenix Field Division.
Cheri Oz leads DEA’s national Diversion Control Division.
Phoenix Diversion personnel carry out regional registration, regulatory, civil, administrative, and criminal work within Arizona.

Older Arizona releases identifying Oz as Special Agent in Charge remain historically accurate for the dates on which they were issued. They should not be used to describe current Phoenix leadership.

Where the public record is deficient

DEA’s current public sources do not provide:

A direct statement that the division serves every Arizona county.
A statewide territorial map.
The present classification of every listed location.
A complete Assistant Special Agent in Charge roster.
The current Diversion Program Manager.
The names of Diversion Group supervisors.
The names of Tactical Diversion Squad supervisors.
The number of Diversion Investigators assigned to Arizona.
County-level office responsibility.
A separate regional registration contact.
A named medical-practitioner compliance official.
A public explanation of how Phoenix and Tucson divide Diversion responsibility.
A public explanation of how northern and western Arizona receive Tactical Diversion support.

DEA’s current biography identifies Nogales and Tucson as district offices during Ruiz’s prior service. That historical or career description does not independently establish whether both retain exactly the same classification under the present organization.

What can be concluded

The Phoenix Field Division is DEA’s operational Arizona command.

Its seven published locations correspond to Arizona’s principal metropolitan areas, international-border corridors, northern region, western river communities, and southeastern border territory.

Current records demonstrate division activity involving:

Sinaloa-linked and other transnational organizations.
Fentanyl pills and fentanyl powder.
Methamphetamine.
Cocaine.
Heroin.
Counterfeit oxycodone and other imitation pharmaceuticals.
Firearms associated with drug trafficking.
Cryptocurrency and cash proceeds.
Interstate distribution networks.
International-border investigations.
Pharmaceutical diversion and controlled-substance compliance.
Joint federal, state, local, and tribal enforcement.

What cannot presently be concluded

The public record does not establish:

Whether each Arizona county is formally assigned to one listed office.
Whether Flagstaff, Lake Havasu, Sierra Vista, and Yuma are resident offices, posts of duty, or another form of field presence.
Whether Phoenix and Tucson Tactical Diversion Squads divide the state geographically.
Which squad serves Flagstaff and northern Arizona.
Which squad serves Lake Havasu and western Arizona.
Whether Nogales and Sierra Vista maintain separate Diversion personnel.
The current Phoenix Diversion Program Manager.
The current number of traditional Diversion Groups.
Whether all regional registration inquiries are handled locally or through DEA’s national Registration Contact Center.
The number of criminal, civil, and administrative Diversion matters initiated annually in Arizona.
The number of registrants inspected, warned, restricted, suspended, surrendered, or prosecuted.

Seeds of Vice will not fill those gaps through assumption.

Who the Phoenix Division Serves

The Phoenix Field Division serves Arizona’s residents, patients, controlled-substance registrants, healthcare institutions, public agencies, and communities.

Its territory includes:

The Phoenix metropolitan region.
Tucson and southern Arizona.
The Nogales border corridor.
The Sierra Vista and Cochise County region.
Yuma and the southwestern border.
Flagstaff and northern Arizona.
Lake Havasu and western Arizona.
Interstate highways connecting Mexico, California, Nevada, New Mexico, Utah, and the remainder of the United States.
Tribal lands and tribal healthcare systems.
Rural communities located far from metropolitan medical centers.
Airports, mail systems, warehouses, highways, and international ports of entry.

The division serves or regulates:

Patients receiving controlled medications.
Physicians and other authorized prescribers.
Pharmacies and pharmacists.
Hospitals and clinics.
Manufacturers and distributors.
Researchers and universities.
Veterinary practices.
Narcotic-treatment programs.
Indian Health Service and tribal facilities.
Federal healthcare facilities.
State and local law-enforcement agencies.
Families affected by illicit fentanyl, methamphetamine, counterfeit pills, addiction, violence, and inadequate medical treatment.

The Phoenix system operates across two fundamentally different controlled-substance channels.

The illicit channel

The illicit channel includes:

Unlawful importation from Mexico.
Fentanyl powder and pill production.
Methamphetamine and cocaine trafficking.
Cartel-linked transportation and distribution.
Counterfeit tablets.
Illicit pill presses.
Firearms associated with drug transactions.
Money laundering.
Cryptocurrency proceeds.
Drug-related violence.
Interstate distribution.
Pharmacy theft and prescription forgery.

The lawful channel

The lawful channel includes:

Registered manufacturers.
Distributors.
Pharmacies.
Hospitals.
Physicians and other practitioners.
Researchers.
Veterinary practices.
Treatment programs.
Patients receiving controlled substances for legitimate medical purposes.

The two channels may intersect when:

Genuine medication is stolen.
A prescription is forged.
A registrant intentionally distributes outside legitimate professional practice.
A pharmacy knowingly dispenses an invalid prescription.
A regulated business fails to maintain required controls.
An illicit manufacturer creates a tablet resembling authentic medicine.

Those intersections do not make every patient, practitioner, pharmacy, hospital, or pharmaceutical company part of the illicit market.

Territory and Office Structure

Phoenix Division Headquarters

3439 East University Drive
Phoenix, Arizona 85034

Main telephone: 571-362-5600

Published Arizona Contacts

Published location	Telephone
Flagstaff	928-323-5447
Lake Havasu	602-722-7153
Nogales	571-324-7066
Sierra Vista	571-362-1180
Tucson	571-324-7218
Yuma	571-324-7324

These are DEA’s current published contacts. Their presence in the directory establishes that DEA provides an official contact associated with each area. It does not, by itself, establish whether each is a district office, resident office, post of duty, permanently staffed facility, shared task-force location, or another organizational unit.

The seven-location structure

The public directory contains:

One Phoenix headquarters.
Six subordinate contacts.

That produces seven locations.

DEA’s biography of Cheri Oz states that she oversaw seven offices throughout Arizona while serving as Phoenix Special Agent in Charge. The present directory therefore appears consistent with the division’s recent seven-office structure.

Nogales and Tucson

Ruiz’s current biography identifies Nogales and Tucson as district offices during his prior service as an Assistant Special Agent in Charge.

That is strong evidence that these locations have held district-office status.

DEA’s current division page, however, does not visibly apply office classifications to any listed location. Seeds of Vice therefore will not represent the historical description as an independently reconfirmed July 2026 organizational designation without qualification.

Statewide coverage without a statewide statement

The division page does not use the simpler wording:

Serving Arizona

Instead, it states that the division serves seven named areas.

This wording creates questions that DEA should answer:

Are the named areas intended to encompass the entire state?
Are any Arizona counties assigned to another field division?
Are the labels office locations, service regions, or both?
What are the boundaries between Phoenix, Tucson, Flagstaff, Lake Havasu, Nogales, Sierra Vista, and Yuma?

Available records support statewide operation, but DEA should state the territorial rule directly.

Current Leadership and Publicly Identified Personnel

Apolonio “Polo” Ruiz Jr.

Special Agent in Charge

Apolonio Ruiz Jr. became Special Agent in Charge of the Phoenix Field Division in January 2026.

Ruiz began his law-enforcement career with the Los Angeles Police Department. His assignments included patrol work, undercover service in anti-terrorism and narcotics units, and participation in DEA’s first Mobile Enforcement Team through the Los Angeles Rampart Task Force.

He joined DEA in June 1998 and completed Basic Agent Class 125 in October of that year.

His DEA career has included:

The El Paso Field Division.
DEA’s Mérida Resident Office in Mexico.
Large transnational investigations involving Colombia, Mexico, and Panama.
Group supervision in the Nogales District Office.
Leadership of DEA’s Mazatlán Resident Office.
Coordination involving major cartel targets.
DEA’s Mexico City Country Office.
Assistant Special Agent in Charge responsibility involving Nogales and Tucson.
Command of the Phoenix Field Division.

DEA credits Ruiz with involvement in operations involving Joaquín “El Chapo” Guzmán-Loera and other senior cartel figures, including coordination with Mexican and United States partner agencies. These descriptions concern Ruiz’s official career history and should not be interpreted as a finding that every current Phoenix investigation directly involves the same organizations or individuals.

Ruiz holds a bachelor’s degree in criminal justice with minors in political science and sociology from the University of Texas at El Paso.

Cheri Oz

Assistant Administrator, Diversion Control Division

Former Phoenix Special Agent in Charge

Cheri Oz was appointed Assistant Administrator of DEA’s national Diversion Control Division in November 2025.

DEA states that she serves as the Administrator’s principal advisor on protecting the controlled-prescription-drug and listed-chemical supply chain, coordinating major pharmaceutical and chemical diversion investigations, developing regulations, establishing production quotas, and overseeing programs affecting approximately 2.2 million registrants.

Oz previously commanded the Phoenix Field Division beginning in March 2020 and oversaw seven offices throughout Arizona. Her move from Phoenix field command to national Diversion leadership is particularly relevant to the division-page project because it demonstrates the institutional distinction between:

Regional field enforcement.
Regional Diversion operations.
National Diversion policy and regulation.

Joshua Boyer

Media Contact

Telephone: 571-362-0582

DEA identifies Joshua Boyer as the Phoenix Division’s media contact.

Recruitment

Telephone: 571-362-0582
Email: PhoenixSpecialAgentRecruiter@dea.gov

The current page uses the same telephone number for media and recruitment and does not identify an individual recruiter by name.

Daniel Morehouse

Community-Outreach Contact

Telephone: 480-995-5136
Email: Daniel.A.Morehouse@dea.gov

Current Diversion leadership

A current Phoenix Field Division Diversion Program Manager could not be verified through a current official public personnel record.

Michael Grafton was publicly identified as Phoenix’s Diversion Program Manager during a 2019 DEA practitioner conference. That identification is historical and should not be treated as evidence that he holds the same office in July 2026.

DEA’s failure to identify current Phoenix Diversion leadership is significant because regional Diversion personnel exercise authority affecting:

Practitioner and pharmacy registration.
Inspections.
Manufacturer and distributor compliance.
Recordkeeping.
Security.
Administrative actions.
Civil referrals.
Criminal diversion investigations.

The officials supervising those functions should be publicly identifiable.

Tactical Diversion Squads

DEA’s current national directory identifies Tactical Diversion Squads in:

Phoenix
Tucson

DEA describes Tactical Diversion Squads as combined federal, state, and local units designed to investigate, disrupt, and dismantle suspected violations involving the diversion of lawfully produced pharmaceutical controlled substances or listed chemicals.

DEA states that these squads:

Combine information and authority from several levels of government.
Coordinate investigations and prosecutions across judicial districts.
Support traditional Diversion Groups when arrests, surveillance, evidence purchases, confidential payments, or search warrants are required.

A Tactical Diversion Squad is therefore not simply a registration or compliance office.

It is an enforcement structure capable of investigating:

Counterfeit pharmaceuticals.
Prescription forgery.
Pharmacy theft.
Illicit pill presses.
Internet distribution.
Unlawful prescribing.
Unlawful dispensing.
Healthcare-related controlled-substance fraud.
Diversion by manufacturers or distributors.
Criminal conduct involving listed chemicals.

Historical Arizona TDS structure

DEA historically stated that its Phoenix Tactical Diversion Squad was established in March 2009 and that criminal and regulatory groups operated in Phoenix and Tucson.

The historical fact sheet described participation by:

Special agents.
Diversion Investigators.
Intelligence personnel.
Federal, state, local, and tribal task-force officers.

It identified potential subjects including physicians, pharmacies, pharmacists, manufacturers, internet pharmacies, prescription forgers, healthcare institutions, and chemical-diversion organizations.

That document is useful historical evidence.

Its phone numbers, personnel, and organizational details should not be assumed to remain current.

Current unanswered questions

DEA does not publicly explain:

Which Arizona counties are assigned to Phoenix TDS.
Which counties are assigned to Tucson TDS.
Whether either squad has statewide authority.
Which squad serves Flagstaff.
Which squad serves Lake Havasu.
Whether Nogales, Sierra Vista, or Yuma maintain attached Diversion personnel.
Whether the Phoenix and Tucson squads report to one Diversion Program Manager.
Whether traditional Diversion Groups use the same boundaries.
How Arizona’s tribal jurisdictions are assigned.
Whether regional registration and criminal Diversion functions share the same organizational structure.

The public can identify that two squads exist.

It cannot reconstruct the complete Arizona Diversion system.

Official Role and Mission

The Phoenix Field Division enforces the federal Controlled Substances Act and related federal laws within its assigned Arizona territory and in connected interstate and international investigations.

Its work may include:

Drug-trafficking investigations.
Intelligence collection and analysis.
Cartel and transnational-organization investigations.
International-border operations.
Fentanyl and counterfeit-pill cases.
Methamphetamine and cocaine investigations.
Firearms and money laundering.
Cryptocurrency tracing and forfeiture.
Controlled-substance registration.
Administrative inspections.
Practitioner and pharmacy investigations.
Manufacturer and distributor oversight.
Theft and loss investigations.
Suspicious-order investigations.
Civil referrals.
Administrative registration actions.
Community outreach.
Prescription-drug disposal.

DEA defines the national Diversion Control mission as preventing, detecting, and investigating the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs.

Those are simultaneous obligations.

Diversion Control is not officially defined solely as:

Reducing prescribing.
Restricting pharmacy supply.
Suspending registrations.
Prosecuting practitioners.
Increasing inspections.

The mission also requires preservation of the lawful supply required by patients, medicine, research, treatment, and commerce.

How the Phoenix System Works in Practice

Arizona as a border and national distribution corridor

Arizona’s international boundary and transportation infrastructure place the Phoenix Division near major supply routes used by organizations moving fentanyl, methamphetamine, cocaine, heroin, and proceeds between Mexico and the United States.

Drugs entering through or stored in Arizona may be:

Distributed within the state.
Sent to other regions.
Concealed in vehicles or commercial shipments.
Stored in metropolitan stash locations.
Packaged into counterfeit tablets.
Exchanged for cash, cryptocurrency, vehicles, or other assets.

Arizona therefore functions as both a local market and a national transportation and distribution point.

March 2026 multiagency operation

In March 2026, DEA and Arizona partner agencies announced the results of a major operation that reportedly produced seizures of:

More than 1,750 pounds of methamphetamine.
More than 113 pounds of cocaine.
More than 11 pounds of fentanyl in pill and powder form.
Heroin.
Marijuana.
Synthetic cannabinoids.
Nearly two dozen firearms.
More than two dozen vehicles.
More than $612,000 in cash.
Approximately $300,000 in cryptocurrency.

DEA described the operation as targeting criminal organizations operating in Arizona communities.

The announcement reported seizures and agency conclusions. It did not, by itself, provide a complete defendant-by-defendant account of charges, pleas, convictions, or dismissals.

The statement that the operation “saved countless lives” is an agency characterization. Seizure totals do not permit an exact independent calculation of deaths prevented.

Fentanyl transaction and shooting involving DEA agents

In February 2026, two defendants were charged after an alleged transaction involving approximately 50,000 fentanyl pills.

Federal authorities alleged that one defendant opened fire when DEA agents attempted to make arrests. A later indictment included attempted murder of a federal officer, assault, firearm, conspiracy, and fentanyl-distribution charges.

The charges are allegations.

The defendants remain presumed innocent unless and until convicted.

This case involves alleged armed trafficking conduct. It is not comparable to an ordinary medical prescribing disagreement, a pharmacy documentation error, or a civil registrant investigation.

Counterfeit oxycodone distribution

In July 2026, Jose De Jesus Martinez received a five-year federal sentence after previously pleading guilty to possession with intent to distribute fentanyl.

Authorities stated that Martinez was caught delivering approximately 150,000 counterfeit oxycodone tablets containing fentanyl near Phoenix in May 2025. Agents reported seizing approximately 13.3 kilograms of drugs.

This was an adjudicated criminal matter based on a guilty plea and sentence.

The tablets were dangerous in part because they were manufactured to resemble legitimate oxycodone while containing illicit fentanyl.

Repeat fentanyl trafficker

In June 2026, a defendant with prior state drug-trafficking convictions received a 144-month federal sentence for fentanyl distribution.

Federal prosecutors stated that the case involved approximately 40,000 fentanyl pills.

The sentence represents an adjudicated disposition, not a pending allegation.

Southern Arizona fentanyl and methamphetamine conspiracy

In January 2026, Sebastian Martinez-Romero received a 78-month federal sentence after pleading guilty to conspiracy to distribute fentanyl and methamphetamine.

The case was prosecuted in Tucson and involved a defendant from Nogales, Sonora.

The matter demonstrates the connection among:

Nogales.
Tucson.
International supply.
Interstate federal enforcement.
The broader Phoenix Field Division.

Arizona-based interstate conspiracy

In June 2026, a Michigan defendant received a 60-month sentence after pleading guilty to participating in an Arizona-based fentanyl conspiracy.

The prosecution demonstrates that an Arizona investigation may involve distributors and participants far outside the state.

Counterfeit Medicine and the Lawful Channel

Counterfeit pharmaceutical tablets are a central Arizona enforcement problem.

An illicit tablet may be designed to resemble:

Oxycodone.
Alprazolam.
Amphetamine medication.
Another familiar prescription product.

The tablet may instead contain:

Illicit fentanyl.
Methamphetamine.
An illicit benzodiazepine.
A mixture of substances.
An inconsistent or unknown dose.

The counterfeit product borrows the physical appearance and implied reliability of lawful medicine while bypassing:

Regulated manufacturing.
Quality control.
Accurate labeling.
Dose uniformity.
A valid prescription.
Pharmacist review.
Traceable distribution.
Patient-specific medical judgment.

That distinction is essential.

The danger of counterfeit medicine supports stronger protection of authentic medicine.

It does not support treating every controlled-substance prescription as though it were counterfeit.

Diversion Control and Lawful Medicine

Phoenix Division Diversion personnel may regulate or investigate:

Physicians.
Dentists.
Nurse practitioners.
Physician assistants.
Pharmacists.
Hospitals.
Clinics.
Veterinary practices.
Manufacturers.
Distributors.
Researchers.
Narcotic-treatment programs.
Tribal and Indian Health Service facilities.
Importers and exporters.
Other DEA registrants.

Their work may include:

Registration applications and renewals.
Scheduled investigations.
Inspections.
Controlled-substance inventories.
Recordkeeping reviews.
Security evaluations.
Theft and loss reporting.
Suspicious-order investigations.
Prescription reviews.
Administrative subpoenas.
Corrective agreements.
Voluntary registration surrender.
Orders to Show Cause.
Immediate Suspension Orders.
Civil referrals.
Criminal investigation when intentional unlawful conduct is suspected.

These actions occupy different legal positions.

Inspection

An inspection is a regulatory or investigative process.

It is not itself proof of wrongdoing.

Corrective action

A registrant may be required or agree to improve:

Inventory.
Security.
Recordkeeping.
Reporting.
Staff training.
Controlled-substance handling.

Corrective action does not automatically establish criminal conduct.

Civil settlement

A civil settlement resolves civil allegations or potential liability.

It is not automatically a guilty plea or criminal conviction.

Administrative action

An administrative action concerns the authority to manufacture, distribute, prescribe, dispense, research, or possess controlled substances.

It may occur independently of criminal prosecution.

Criminal complaint or indictment

A criminal charge is an allegation.

The accused remains presumed innocent unless convicted.

Guilty plea

A guilty plea is a formal admission to specified criminal conduct.

Trial conviction

A trial conviction is an adjudicated finding of guilt.

Sentence

A sentence follows a plea or conviction.

The word enforcement should never erase these distinctions.

Historical Phoenix Diversion Practice

DEA held a practitioner Diversion-awareness conference in Phoenix in July 2019 for more than 450 registrants.

The program included instruction concerning:

Legitimate medical practice.
Drug trends.
Controlled-substance prescriptions.
Diversion methods.
Inventories and records.
DEA registration.
Disposal and return of patient medication.
Telemedicine.
Arizona’s Prescription Monitoring Program.
State medical-board responsibilities.

The conference demonstrates that Phoenix Diversion activity has included education and registrant outreach in addition to inspections and enforcement.

It also demonstrates why the current Diversion Program Manager and outreach structure should be publicly identified.

A historical conference cannot substitute for a current organizational chart.

Arizona’s State-Control Layer

DEA’s federal authority operates alongside:

Arizona statutes.
The Arizona State Board of Pharmacy.
The Arizona Controlled Substances Prescription Monitoring Program.
Professional licensing boards.
The Arizona Department of Health Services.
Insurers.
Pharmacy corporations.
Hospitals and clinics.
Civil-liability systems.
Individual medical judgment.

DEA does not independently create or administer every rule affecting Arizona controlled-substance treatment.

Arizona Controlled Substances Prescription Monitoring Program

Arizona’s CSPMP is a state database that collects dispensing information for Schedule II through Schedule V controlled substances. Prescribers with active Arizona DEA registrations and pharmacists in covered practice settings are required to register for access.

Arizona law generally requires a medical practitioner to obtain a 12-month patient-utilization report:

At the beginning of each new course of treatment involving a covered opioid analgesic or benzodiazepine.
At least quarterly while the medication remains part of treatment.

The statute contains specified exceptions, including certain cancer, hospice, palliative, inpatient, skilled-nursing, acute-procedure, and acute-injury circumstances.

Arizona also generally requires a pharmacist to review a 12-month patient report at the beginning of a new course of treatment before dispensing a Schedule II controlled substance, subject to applicable statutory provisions.

A monitoring report is information.

It is not, by itself, proof that:

A patient committed a crime.
A patient is deceptive.
A patient has a substance-use disorder.
A prescription lacks legitimate medical purpose.
A practitioner acted outside professional practice.
A pharmacist knowingly dispensed unlawfully.

Those conclusions require context and additional evidence.

Initial Schedule II opioid limits

Arizona law generally limits an initial Schedule II opioid prescription to no more than a five-day supply.

An initial prescription following a surgical procedure is generally limited to no more than a 14-day supply.

The statute contains exceptions for patients who:

Have an active oncology diagnosis.
Have a traumatic injury other than the surgical procedure itself.
Receive hospice care.
Receive end-of-life care.
Receive palliative care.
Receive skilled-nursing-facility care.
Receive burn treatment.
Receive medication-assisted treatment for a substance-use disorder.
Are infants being weaned from opioids at discharge.

Arizona defines an “initial prescription” through the absence of a covered Schedule II opioid prescription during the preceding 60 days, as reflected in the CSPMP.

The five-day rule should not be represented as:

A universal five-day limit on every opioid prescription.
A rule prohibiting continued chronic-pain treatment.
A rule without exceptions.
A federal DEA requirement.
A complete medical standard of care.

Dosage controls

Arizona’s Opioid Epidemic Act established restrictions involving new opioid prescriptions above 90 morphine milligram equivalents per day, subject to statutory exceptions, continuation provisions, and consultation mechanisms. It also established requirements involving naloxone in specified high-dose circumstances.

A state statutory threshold is not the same as a scientific finding that every patient above the threshold is being treated improperly.

The legal effect depends on:

Whether the prescription is new or continuing.
The patient’s condition.
Applicable exemptions.
The prescriber’s specialty.
Consultation requirements.
The exact statutory language in force.

Electronic prescribing

Arizona generally requires electronic prescribing for Schedule II opioid prescriptions, subject to statutory exceptions for system failure, certain federal or tribal facilities, hospice, long-term-care settings, emergencies, and other defined circumstances.

Electronic prescribing may reduce forgery and improve traceability.

It does not independently determine whether a prescription is clinically appropriate.

How the System Affects Pain Patients and Lawful Medicine

Legitimate protective functions

A functioning Diversion system can protect patients by:

Detecting forged prescriptions.
Investigating pharmacy theft.
Enforcing accurate inventory.
Identifying counterfeit tablets.
Identifying illicit pill presses.
Investigating intentional criminal prescribing.
Investigating knowing unlawful dispensing.
Preventing stolen medication from entering illicit markets.
Preserving traceability within the lawful channel.
Separating authentic pharmaceuticals from counterfeit fentanyl products.
Holding registrants accountable for intentional unlawful conduct.

Arizona’s counterfeit-pill cases demonstrate why lawful pharmaceutical integrity matters.

A person may believe a tablet is oxycodone because of its appearance and marking while receiving a substance produced without dosage control or pharmaceutical safeguards.

Risk of institutional overcorrection

The same control environment can harm legitimate patients when:

Numerical thresholds become automatic rules.
Monitoring data become verdicts.
Practitioners stop treating pain because they fear investigation.
Pharmacies refuse lawful prescriptions through unpublished policies.
Patients are rapidly tapered.
Medication is abruptly discontinued.
Patients are dismissed from care.
Drug testing and contracts become punitive rather than clinical.
Risk management replaces individualized judgment.
Alternatives are assumed to be available without determining whether a patient can obtain them.

CDC’s current guidance states that opioid therapy should not be abruptly discontinued or rapidly reduced unless a life-threatening issue requires immediate action. It instructs clinicians to weigh patient-specific benefits and risks and to work closely with patients when continuation, tapering, or discontinuation is considered.

That does not establish that DEA alone causes undertreatment.

The treatment environment is produced through the combined actions of:

Congress.
DEA.
Federal prosecutors.
Arizona lawmakers.
State licensing boards.
The CSPMP.
Insurers.
Pharmacy corporations.
Hospitals and clinics.
Professional organizations.
Civil-liability systems.
Individual practitioners.
Patients.
The illicit market.

DEA should not be assigned sole responsibility for every medical decision.

It should not be removed from the analysis.

The possibility of inspection, registration restriction, administrative action, civil penalties, criminal referral, or prosecution is part of the institutional environment in which controlled-substance decisions are made.

Rural, tribal, and border-region effects

Arizona contains communities located substantial distances from:

Pain specialists.
Large hospital systems.
Independent pharmacies.
Physical therapy.
Behavioral-health services.
Interventional treatment.
Addiction-treatment programs.
Public transportation.
Metropolitan DEA and state regulatory offices.

The practical effect of a prescribing, monitoring, drug-testing, pharmacy, or referral requirement may therefore differ greatly among:

Phoenix.
Tucson.
Flagstaff.
Yuma.
Tribal communities.
Rural northern Arizona.
Western Arizona.
Southeastern border communities.

An alternative is not functionally available merely because it exists somewhere in the state or appears in a guideline.

A serious access analysis must ask whether the patient can:

Reach it.
Afford it.
Obtain insurance approval.
Tolerate it.
Receive it within a clinically meaningful period.
Benefit from it.

Prescribing and Dose-Decline Context

Evidentiary boundary

Seeds of Vice begins its historical inquiry in 1984.

No continuous, directly comparable annual Arizona retail opioid-dispensing series was identified for every year beginning in 1984.

The record must therefore be divided into defensible evidentiary periods.

1984–2005

Historical inquiry may use:

Federal distribution records.
Manufacturing and production data.
Controlled-substance quota records.
Medicaid and insurer utilization.
Drug-specific studies.
Medical literature.
Arizona regulatory history.
National prescribing indicators.

Those sources cannot be silently merged with the later CDC retail-pharmacy dispensing series.

Missing annual values should not be interpolated.

Selected CDC retail-dispensing benchmarks

The following figures represent retail opioid prescriptions dispensed per 100 residents:

Year	Arizona rate
2006	74.3
2011	88.6
2012	85.3
2016	70.2
2019	44.1
2023	34.7

Arizona’s highest rate within these reviewed benchmark years was 88.6 prescriptions per 100 residents in 2011.

Calculated decline

From the reviewed 2011 high of 88.6 to the 2023 rate of 34.7, Arizona’s retail opioid-dispensing rate declined by approximately:

60.8 percent

From 2006 through 2023, the decline was approximately:

53.3 percent

From 2019 through 2023, the decline was approximately:

21.3 percent

These percentages are Seeds of Vice calculations based on the reported rates.

Arizona CSPMP 2024 total

Arizona’s state CSPMP reported that 3,935,380 opioid prescriptions were dispensed in 2024, a 12.5 percent decline from 4,499,834 in 2019.

That state total should not be treated as automatically interchangeable with CDC’s IQVIA rate series.

The two systems may differ in:

Reporting population.
Covered dispensers.
Geographic assignment.
Drug definitions.
Projection methodology.
Inclusion and exclusion rules.

The state report is useful as a separate utilization indicator.

It should not be silently converted into a CDC-equivalent rate.

County variation

Arizona’s CSPMP reports substantial county variation.

Its 2024 material identified Maricopa County at approximately 409.59 opioid prescriptions per 1,000 residents, equivalent to approximately 40.96 per 100 under the state report’s measure.

County figures require particular caution because a rate may be influenced by:

Prescriber concentration.
Patient travel.
Pharmacy distribution.
Population age.
Rural access.
Regional hospitals.
Specialty practices.
The dataset’s geographic methodology.

A high county rate does not prove unlawful prescribing.

A low county rate does not prove adequate treatment.

2024 national context

CDC reported that the national retail opioid-dispensing rate was 35.4 prescriptions per 100 residents in 2024, down from 46.8 in 2019.

An exact Arizona 2024 CDC rate was not visible in the accessible static federal text reviewed for this page.

The latest fully transcribed Arizona CDC rate presented here therefore ends in 2023.

The 2024 state value should be added only after direct verification from the underlying CDC data table.

It should not be estimated from map shading, Arizona’s state PMP total, or surrounding annual values.

Methodological limits

CDC’s current estimates use IQVIA Xponent information projected from approximately 54,600 nonhospital retail pharmacies representing nearly 94 percent of United States retail prescriptions.

The dataset:

Includes new and refilled retail prescriptions.
Includes several payment sources.
Excludes mail-order prescriptions.
Excludes methadone dispensed through opioid-treatment programs.
Uses the prescriber’s location in the current series.
Does not establish whether the patient consumed the medication.
Does not establish whether treatment was medically appropriate.
Does not measure pain severity.
Does not measure patient function.
Does not identify voluntary versus involuntary discontinuation.

CDC changed geographic attribution beginning in 2019 from the dispensing pharmacy’s location to the prescriber’s location. That change should be considered when comparing earlier and later rates.

Prescriptions per 100 residents must not be mixed with:

MME per capita.
Average MME per prescription.
Daily dosage.
Days supplied.
Number of patients.
Number of tablets.
Total controlled-substance prescriptions.
Overdose deaths.
Drug-seizure quantities.

Each measure answers a different question.

Overdose Context

Arizona reported 1,928 opioid-overdose deaths among state residents in 2023.

The state’s annual opioid-overdose fatality rate was 25.6 per 100,000 residents. Arizona classified approximately 93.7 percent of those deaths as accidental.

The Arizona report stated that prescription and synthetic opioids—including illicit fentanyl within that category—contributed to approximately 97.6 percent of opioid-overdose deaths.

That category should not be read as proof that prescribed medication caused 97.6 percent of deaths. The classification combines prescription and synthetic opioids and expressly includes illicit fentanyl.

The highest county opioid-fatality rates were reported in:

Apache County.
Navajo County.
Gila County.
Pima County.
Maricopa County.

The state also reported substantial disparities by age, sex, race, ethnicity, and geography.

Those disparities demonstrate that overdose risk is not distributed evenly across Arizona. They do not independently identify the cause of each disparity.

Maricopa County drug combinations

Maricopa County reported that, among fatal overdoses in 2024:

Fentanyl was involved in approximately 59 percent.
Methamphetamine was involved in approximately 67 percent.

The percentages can overlap because one death may involve more than one substance.

They should not be added together or treated as mutually exclusive categories.

What the combined record establishes

Arizona experienced:

A retail opioid-dispensing decline exceeding 60 percent from its reviewed high through 2023.
Continuing high levels of illicit fentanyl and methamphetamine harm.
Large seizures of methamphetamine, fentanyl, and cocaine.
Counterfeit pills designed to resemble lawful pharmaceuticals.
Nearly 2,000 opioid-overdose deaths in 2023.
Extensive polysubstance involvement in later county data.

Those facts can exist simultaneously.

They do not prove that:

Every prescribing reduction was medically appropriate.
Every patient retained adequate pain treatment.
DEA enforcement alone caused a mortality change.
The CSPMP alone caused a mortality change.
Naloxone alone caused a mortality change.
Treatment availability alone explains the results.
Lawful opioid prescriptions are the principal current source of Arizona’s illicit fentanyl market.

A reduction in lawful prescribing does not prove that illicit markets disappeared.

The presence of illicit fentanyl does not establish that every legitimate pain patient received adequate care.

Representative Phoenix Division Matters

Major Arizona multiagency seizures

Enforcement operation

DEA and partner agencies reported seizing more than 1,750 pounds of methamphetamine, 113 pounds of cocaine, 11 pounds of fentanyl, firearms, vehicles, cash, and cryptocurrency.

The announcement described the operation’s results but did not provide a complete defendant-by-defendant adjudicative record.

Alleged 50,000-pill transaction and shooting

Indictment and pending charges

Two defendants were charged after an alleged fentanyl transaction during which one defendant allegedly fired at DEA agents.

The charges include serious drug, firearm, assault, and attempted-murder allegations.

The defendants remain presumed innocent unless convicted.

Avondale counterfeit-oxycodone case

Guilty plea and sentence

Jose De Jesus Martinez received a five-year sentence after pleading guilty in a matter involving approximately 150,000 counterfeit oxycodone tablets containing fentanyl.

This was an adjudicated criminal disposition.

Repeat fentanyl trafficker

Sentence

A defendant received a 144-month federal sentence in a matter involving approximately 40,000 fentanyl pills.

The sentencing was an adjudicated outcome, not a pending allegation.

Nogales–Tucson fentanyl and methamphetamine case

Guilty plea and sentence

Sebastian Martinez-Romero received a 78-month sentence after pleading guilty to conspiracy to distribute fentanyl and methamphetamine.

The matter reflects the division’s international-border and southern-Arizona operating environment.

Arizona-based interstate conspiracy

Guilty plea and sentence

A Michigan defendant received a 60-month sentence after pleading guilty to an Arizona-based fentanyl conspiracy.

The case demonstrates that Phoenix Division investigations may extend through national distribution networks.

Historical pain-clinic investigation

Indictment

In 2011, a physician and clinic administrator were indicted on allegations involving controlled-substance prescriptions, healthcare fraud, and money laundering.

The investigation involved Phoenix Tactical Diversion personnel and partner agencies.

The indictment was an allegation at the time of the announcement and should not be described as a conviction without reviewing the later case disposition.

The historical matter is included to demonstrate the type of registrant investigation conducted through Phoenix’s Diversion system—not as a current case or current personnel record.

Operation Engage Glendale

DEA’s Phoenix page identifies Operation Engage Glendale as the division’s current community-focused initiative.

DEA describes its local purpose as eliminating the drug threat and engaging community leadership to reduce drug misuse.

Operation Engage combines elements such as:

Enforcement.
Prevention.
Education.
Community outreach.
Partnerships.
Local drug-threat assessment.

It is an initiative within the Phoenix Field Division.

It is not:

A separate field division.
A substitute for statewide enforcement.
A substitute for Diversion Control.
A permanent jurisdictional boundary.
Proof that Glendale is the only Arizona community receiving concentrated attention.

Program activity and results should be evaluated separately from the division’s permanent criminal, regulatory, and administrative responsibilities.

Contact Information

Phoenix Field Division Headquarters

Address:
3439 East University Drive
Phoenix, Arizona 85034

Main telephone: 571-362-5600

Media

Joshua Boyer
Telephone: 571-362-0582

Recruitment

Telephone: 571-362-0582
Email: PhoenixSpecialAgentRecruiter@dea.gov

Community Outreach

Daniel Morehouse
Telephone: 480-995-5136
Email: Daniel.A.Morehouse@dea.gov

Published Arizona Contacts

Flagstaff: 928-323-5447
Lake Havasu: 602-722-7153
Nogales: 571-324-7066
Sierra Vista: 571-362-1180
Tucson: 571-324-7218
Yuma: 571-324-7324

National DEA Registration Contact

Registration Contact Center: 800-882-9539

DEA’s current Phoenix page does not publish:

A named regional registration official.
A Phoenix-specific registration email.
A Tucson-specific registration contact.
A current Diversion Program Manager.
A named practitioner-compliance official.

Callers should verify whether a matter belongs to:

Phoenix headquarters.
A geographic field office.
Phoenix Tactical Diversion Squad.
Tucson Tactical Diversion Squad.
A traditional Diversion Group.
The national Registration Contact Center.
The national Diversion Control Division.

That process should be clearer from DEA’s public directory.

Seeds of Vice Analysis

The Phoenix Division’s territorial problem is not a major jurisdictional conflict.

All available evidence supports one Arizona field command.

The problem is that DEA communicates that command through a list of service areas rather than a transparent statewide organizational map.

The public receives:

One headquarters.
Six subordinate contacts.
Seven named service areas.
An office-type legend.
No classifications attached to the individual offices.
Two Tactical Diversion Squad locations.
No current Diversion Program Manager.
No Diversion organization chart.
No county assignments.
No named regional registration official.
No direct statement that every Arizona county is served by Phoenix.

These are not findings of corruption or illegality.

They are findings of incomplete public administration.

Phoenix occupies a distinct national position

Arizona is not merely another domestic drug market.

Its geography places the division close to:

International production and supply networks.
Border crossings.
Cartel-controlled routes.
Major interstate distribution systems.
Cross-country sources and destinations.
Large-scale cash and cryptocurrency movement.

This creates a legitimate need for intensive criminal enforcement.

It also creates a risk that the exceptional scale of the illicit market will dominate every controlled-substance discussion, including discussions about lawful medicine.

The two systems must remain distinct.

Methamphetamine and fentanyl are simultaneous threats

The March 2026 operation produced far more methamphetamine by weight than fentanyl.

Arizona’s overdose record nevertheless shows the extraordinary lethality associated with fentanyl and polysubstance use.

This illustrates why drug threats cannot be measured through one statistic.

Weight does not equal toxicity.
Pill count does not equal number of users.
“Potentially lethal doses” do not equal confirmed prevented deaths.
Seizures do not equal total market availability.
Arrests do not equal convictions.
Prescription decline does not equal overdose decline.

Each measure answers a different institutional question.

Counterfeit medicine is the opposite of lawful medicine

Counterfeit tablets are dangerous because they imitate the trusted appearance of regulated products.

That strengthens the case for:

Authentic manufacturing.
Reliable dosage.
Accurate labeling.
Valid prescriptions.
Licensed pharmacies.
Pharmacist review.
Traceable distribution.
Individualized medical judgment.

It does not justify treating every lawful patient as a suspected counterfeit buyer.

A patient receiving prescribed pain medication from a licensed practitioner and pharmacy is not situated like a person delivering 150,000 fentanyl tablets made to resemble oxycodone.

A physician documenting good-faith treatment is not situated like an organization operating an illicit pill press.

A pharmacy maintaining lawful inventory is not situated like a trafficking organization.

A patient appearing in the CSPMP has not been convicted of anything.

The system must preserve those distinctions.

Arizona’s state rules are unusually consequential

Arizona combines:

Mandatory CSPMP review.
A five-day initial Schedule II opioid limit.
A 14-day postsurgical initial limit.
High-dose statutory controls.
Electronic-prescribing requirements.
Multiple professional licensing systems.
DEA registration.
Pharmacy and insurer policies.

Each rule may serve a legitimate protective purpose.

Together, they create a dense permission system surrounding controlled medicine.

That density requires careful institutional accounting.

The relevant question is not merely whether each rule can be defended independently.

The question is what happens to the patient when all of the rules operate at once.

The prescribing decline is structural

Arizona’s reviewed retail opioid-dispensing rate fell from 88.6 prescriptions per 100 residents in 2011 to 34.7 in 2023.

That is a decline of approximately 60.8 percent.

It is not a marginal adjustment.

It is a transformation in lawful medicine.

The statistics do not prove that the entire decline was harmful.

They do not prove that the entire decline was beneficial.

They establish that substantially less lawful opioid medicine was dispensed per resident.

A complete account should ask:

Which prescriptions were unnecessary?
Which patients benefited from safer treatment?
Which patients received effective alternatives?
Which patients were voluntarily tapered?
Which patients were tapered against their wishes?
Which lost a practitioner?
Which lost a pharmacy?
Which could not travel to specialty care?
Which remained in severe pain?
Which recovered function?
Which lost function?
Which entered the illicit market?
Which withdrew from medical care?
Which died from overdose, suicide, disease, heat exposure, or unrelated causes?
Which outcomes were measured?
Which disappeared from institutional records when the prescription ended?

Dispensing data cannot answer those questions by themselves.

Arizona’s overdose record does not close the inquiry

Arizona continued to experience nearly 2,000 opioid-overdose deaths in 2023 after lawful retail opioid dispensing had fallen dramatically.

That does not prove that prescribing reductions caused the deaths.

It does establish that prescription contraction did not eliminate the illicit overdose crisis.

Likewise, the existence of illicit fentanyl does not prove that legitimate opioid treatment lacks medical value.

Both realities must remain visible:

Illicit fentanyl kills.
Counterfeit pills kill.
Methamphetamine and polysubstance use contribute heavily to mortality.
Intentional unlawful prescribing can cause harm.
Abrupt loss of legitimate treatment can also cause harm.
Monitoring can protect patients.
Monitoring can be misused.
Enforcement can preserve the lawful channel.
Overcorrection can make the lawful channel inaccessible.

The existence of one harm does not erase another.

Rural and tribal access must be measured

A policy developed in Phoenix may impose a different burden in:

Northern Arizona.
Western Arizona.
Reservation communities.
Rural Cochise County.
The Yuma region.
Small border communities.

A patient may be required to obtain:

Repeated in-person visits.
Toxicology testing.
Specialist consultation.
Physical therapy.
Imaging.
Pharmacy access.
Electronic prescriptions.
Regular CSPMP review.
Insurance approval.

Those requirements may be manageable in a large metropolitan healthcare system and practically impossible in a remote community.

A lawful alternative is not meaningful unless it is accessible.

The transition from Oz to Ruiz is institutionally revealing

Cheri Oz moved directly from commanding Phoenix to leading the national Diversion Control Division.

Her biography emphasizes both criminal enforcement and the regulation of the legitimate controlled-substance supply chain.

That transition demonstrates how closely DEA’s enforcement and permission systems are connected.

It also reinforces the need to distinguish their roles.

A Special Agent in Charge commands a regional field division.

The Assistant Administrator of Diversion Control governs national regulatory programs.

Regional Diversion personnel operate between those structures.

The public should be able to see that chain clearly.

The dual mandate is the proper standard

DEA’s official mission requires it to prevent diversion while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs.

Seeds of Vice accepts the first obligation.

It insists upon the second.

The Phoenix system should be capable of:

Interdicting industrial quantities of methamphetamine without treating ordinary medical care as equivalent conduct.
Prosecuting counterfeit-fentanyl distribution without treating every controlled-substance patient as deceptive.
Investigating forged prescriptions without presuming every early refill is criminal.
Regulating pharmacies without creating avoidable access deserts.
Using CSPMP data without converting it into an automatic verdict.
Applying state dosage rules without pretending a number replaces clinical judgment.
Protecting border communities from cartel-supplied drugs while preserving authentic medicine.
Accounting for rural and tribal access before representing alternatives as practically available.

Drug control governs crime.

Diversion control governs permission.

Across Arizona, that permission is administered through one field division, seven published locations, two Tactical Diversion Squads, traditional Diversion personnel, the Arizona CSPMP, professional boards, insurers, pharmacies, hospitals, clinics, tribal and federal healthcare systems, and individual practitioners.

No single institution bears sole responsibility for the final treatment environment.

Every institution exercising authority bears responsibility for its part.

Recommended Public Disclosures

DEA should publish:

A direct statement that the Phoenix Field Division serves the entire State of Arizona, or a precise description of any exception.
A statewide territorial map.
County-level office assignments.
The classification of all six subordinate contacts.
Confirmation of the current status of the Nogales and Tucson District Offices.
A complete current Assistant Special Agent in Charge roster.
The current Phoenix Diversion Program Manager.
The names or positions supervising traditional Diversion Groups.
The names or positions supervising Phoenix and Tucson Tactical Diversion Squads.
The territory assigned to each Tactical Diversion Squad.
An explanation of how northern and western Arizona receive Diversion support.
A named regional registration official.
A Phoenix-specific registration email and telephone number.
Clear practitioner, pharmacy, manufacturer, and distributor compliance contacts.
Annual statistics separating criminal, civil, regulatory, and administrative Diversion matters.
Outcomes distinguished by inspection, warning, corrective agreement, settlement, surrender, suspension, indictment, plea, trial conviction, acquittal, dismissal, and final administrative order.
County- or region-specific reporting rather than only statewide aggregate statistics.
Measures of legitimate medical access alongside enforcement statistics.
Reporting concerning registration delays, practitioner departures, pharmacy refusals, shortages, and rural treatment access.
A clear public explanation of how regional Diversion personnel interact with the national Diversion Control Division.

Publishing these facts would not require disclosure of confidential investigative methods.

It would establish ordinary institutional accountability.

Methodology and Evidentiary Limits

This page prioritizes current primary sources from:

The Drug Enforcement Administration.
DEA’s Diversion Control Division.
The United States Attorney’s Office for the District of Arizona.
The Arizona Legislature.
The Arizona State Board of Pharmacy.
The Arizona Department of Health Services.
Maricopa County.
The Centers for Disease Control and Prevention.

The following evidentiary rules were applied:

The regional command was correctly identified as the Phoenix Field Division.
The field division was distinguished from the national Diversion Control Division.
The January 2026 leadership transition was preserved.
Older records identifying Cheri Oz as Phoenix Special Agent in Charge were treated as historical.
Apolonio Ruiz Jr. was identified as the current Special Agent in Charge.
The page’s area-based service statement was not silently rewritten as an express official statewide statement.
Available evidence supporting statewide operation was presented separately.
Office classifications were not invented.
Historical references to Nogales and Tucson as district offices were qualified.
Tactical Diversion Squad locations were reproduced as DEA currently publishes them.
Historical TDS personnel and telephone numbers were not represented as current.
A current Diversion Program Manager was not invented.
Allegations were distinguished from guilty pleas, convictions, and sentences.
Seizure claims were not converted into exact numbers of deaths prevented.
Agency characterizations were identified as agency characterizations.
Arizona law was separated from federal DEA authority.
Initial prescription limits were not represented as universal chronic-pain limits.
Statutory exceptions were preserved.
CSPMP data were not treated as proof of wrongdoing.
Arizona CSPMP totals were not silently converted into CDC/IQVIA rates.
Prescriptions per 100 residents were not mixed with MME, patient counts, tablet counts, days supplied, or mortality.
Missing historical years were not interpolated.
CDC’s geographic-methodology change was acknowledged.
An unverified 2024 CDC Arizona rate was not estimated.
Prescribing decline was not represented as proof of either medical benefit or patient harm.
Overdose outcomes were not attributed to one institution or intervention.
DEA was analyzed as one institution within a broader medical-control system.
Official mission statements were separated from Seeds of Vice analysis.